AstraZeneca, US6549022043

AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success

Published on 09/10/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock drew fresh attention on September 9, 2026, as RBC set a GBP 145.00 target and highlighted pipeline strength. On the same day, Berenberg lifted COPD drug assumptions, underscoring the growth story behind AstraZeneca stock.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht — AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock (ISIN US6549022043) was trading at USD 160.05 on the New York Stock Exchange as of September 8, 2026, valuing the company at about USD 248.23 billion and placing the shares within a 52-week range of USD 145.79 to USD 212.71.

Analysts sharpen views after COPD data

According to Seeking Alpha on September 9, 2026, RBC Capital Markets initiated coverage of AstraZeneca with an Outperform rating and a price target of 14,500 pence on the London-listed shares, citing a favorable risk-reward profile and pipeline optionality.

As Boerse.de reported on September 10, 2026, Berenberg reiterated its Buy rating on AstraZeneca and kept its price target at 160.00 pence after what it described as outstanding COPD trial data, increasing its estimated probability of market entry for the tozorakimab respiratory drug to 95 percent.

COPD trial results underpin growth narrative

In late-stage trials presented during a medical meeting in Barcelona and summarized on September 9, 2026, a drug being developed by AstraZeneca for chronic obstructive pulmonary disease, tozorakimab, reduced moderate-to-severe COPD exacerbations by about 29 percent to 34 percent versus placebo over the course of a year, according to KFGO.

The same report noted that in two separate studies, former and current smokers receiving tozorakimab had overall moderate or severe exacerbation rates of 1.41 and 1.44 events respectively, compared with 2.00 and 2.03 events among those on placebo, highlighting a meaningful absolute reduction in flare-ups that could translate into significant clinical and commercial value if the drug reaches the market.

Latest quarterly figures and margin performance

MarketBeat data cited by Ad-hoc-news show that in the most recent quarter ended June 30, 2026, AstraZeneca generated revenue of USD 15.38 billion, up 6.4 percent year on year, while earnings per share came in at USD 2.63 compared with a consensus estimate of USD 2.50.

In the same quarterly period, AstraZeneca’s net margin stood at 17.02 percent, illustrating a combination of mid-single-digit top-line growth and solid profitability that underpins the moderate-buy rating profile described by analyst overviews.

According to MarketBeat on September 10, 2026, AstraZeneca currently carries an average analyst rating of Moderate Buy, with fourteen Buy, two Hold and one Sell recommendations and an average price target of USD 206.67.

Valuation metrics and dividend profile

On September 9, 2026, a valuation review by GuruFocus highlighted that AstraZeneca’s share price of USD 157.97 stood about 12.5 percent below its GF Value estimate of USD 180.52, suggesting modest undervaluation on that specific metric.

The same analysis pointed to a dividend yield of 2.02 percent with a payout ratio of 47 percent and modest dividend growth over the past three years, supporting the case for a sustainable income stream alongside the company’s growth ambitions, which could appeal to investors looking for a balance between defense and upside.

Risk factors and divergent analyst opinions

While several houses remain constructive, there are notable dissenting voices: Deutsche Bank maintained a Sell rating on AstraZeneca with a price target of 11,500 pence on the London listing, according to an item on September 10, 2026 from Zonebourse.

The same overview shows AstraZeneca’s London-traded shares at around 11,647 pence, down about 0.03 percent at the time of that snapshot and roughly 15.51 percent lower year-to-date, underlining that, despite supportive COPD data and upbeat calls from RBC and Berenberg, some analysts remain cautious about valuation, execution risks and recent late-stage trial setbacks in other therapeutic areas.

Stock level and next earnings date

Per price and trading statistics presented by Ad-hoc-news, AstraZeneca stock closed at USD 160.05 on the New York Stock Exchange on September 8, 2026, after trading between USD 159.40 and USD 163.96 during that session on volume of about 5.14 million shares.

The same data set lists a next earnings date of October 30, 2026, which will give investors a fresh checkpoint on whether the mid-2026 revenue growth of 6.4 percent and EPS of USD 2.63 can be maintained or improved as pipeline catalysts like the COPD program move closer to potential regulatory milestones.